Why the STAR-121 discontinuation matters for Arcus Biosciences

Arcus Biosciences (RCUS) halted its Phase 3 STAR-121 lung cancer trial with Gilead after a futility analysis found no benefit over the control regimen, and Gilead also stepped back from expanding certain early-stage pipeline options.

Despite the STAR-121 setback and Gilead narrowing its option rights, Arcus Biosciences’ 30-day share price return of 25.74% and 1-year total shareholder return above 200% indicate that recent momentum has been building rather than fading.

If you are weighing what these moves might mean for cancer drug developers more broadly, it can be helpful to see how other healthcare names are trading using our screener of 33 healthcare AI stocks

With Arcus Biosciences still loss making on US$247 million of revenue, yet trading at US$25.50 with a very large modeled intrinsic discount, recent double digit returns raise the key question: is there still an opportunity here or has the market already priced in future growth?

Most Popular Narrative: 25.4% Undervalued

At a last close of $25.50 versus a narrative fair value of $34.20, Arcus Biosciences is framed as meaningfully discounted, with that gap tied closely to how its late stage kidney cancer plans play out.

Arcus Biosciences is prioritizing the launch of its late-stage development program for the HIF-2 alpha inhibitor, casdatifan, which has shown significant efficacy differentiation relative to existing market competitors. This could enhance future revenue through competitive advantage in the RCC market.

Curious what justifies that higher fair value? The narrative refers to future kidney cancer data, potential changes in margins, and an earnings multiple that assumes a different profit profile.

Result: Fair Value of $34.20 (UNDERVALUED)

However, there is still real risk here, because regulatory decisions and competing kidney cancer therapies are both capable of undermining the current upside narrative.

Another View: When Ratios Tell a Different Story

That 25.4% narrative discount lines up with analysts seeing upside, but the current P/S of 12.9x sends a mixed signal. It is higher than the US Biotechs average of 10.9x, below peers at 18.6x, and far above the 1.2x fair ratio, which points to meaningful valuation risk if sentiment cools.

For a closer look at how this pricing gap compares with fundamentals, check the detailed valuation breakdown, including the fair ratio and peer checks, in our See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mix of optimism and caution in this story, it makes sense to move quickly, review the full data set, and decide where you stand using our summary of 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one company here, you could miss out on other ideas that better fit your goals, time horizon, and risk comfort.

• Target potential mispricing by scanning for quality names trading below their estimated worth using the 54 high quality undervalued stocks.
• Prioritise capital protection and steady compounding by checking companies highlighted in the 73 resilient stocks with low risk scores.
• Hunt for future leaders that are flying under most investors’ radar with the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.